RT001 in Progressive Supranuclear Palsy-Clinical and In-Vitro Observations.
PSP
PUFA
RT001
deuteration
lipid peroxidation
mesenchymal stem cells
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
27
05
2021
revised:
18
06
2021
accepted:
22
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Progressive supranuclear palsy (PSP) is a progressive movement disorder associated with lipid peroxidation and intracerebral accumulation of tau. RT001 is a deuterium reinforced isotopologue of linoleic acid that prevents lipid peroxidation (LPO) through the kinetic isotope effect. The effects of RT001 pre-treatment on various oxidative and bioenergetic parameters were evaluated in mesenchymal stem cells (MSC) derived from patients with PSP compared to controls. In parallel, 3 patients with PSP were treated with RT001 and followed clinically. MSCs derived from PSP patients had a significantly higher rate of LPO (161.8 ± 8.2% of control; MSCs derived from patients with PSP have elevated basal levels of LPO, ROS, and mitochondrial dysfunction. These findings are reversed after incubation with RT001. In PSP patients, the progression of disease may be reduced by treatment with RT001.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive supranuclear palsy (PSP) is a progressive movement disorder associated with lipid peroxidation and intracerebral accumulation of tau. RT001 is a deuterium reinforced isotopologue of linoleic acid that prevents lipid peroxidation (LPO) through the kinetic isotope effect.
METHODS
METHODS
The effects of RT001 pre-treatment on various oxidative and bioenergetic parameters were evaluated in mesenchymal stem cells (MSC) derived from patients with PSP compared to controls. In parallel, 3 patients with PSP were treated with RT001 and followed clinically.
RESULTS
RESULTS
MSCs derived from PSP patients had a significantly higher rate of LPO (161.8 ± 8.2% of control;
CONCLUSIONS
CONCLUSIONS
MSCs derived from patients with PSP have elevated basal levels of LPO, ROS, and mitochondrial dysfunction. These findings are reversed after incubation with RT001. In PSP patients, the progression of disease may be reduced by treatment with RT001.
Identifiants
pubmed: 34202031
pii: antiox10071021
doi: 10.3390/antiox10071021
pmc: PMC8300819
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Med Res Methodol. 2006 Jun 13;6:26
pubmed: 16772027
Free Radic Biol Med. 2011 Jan 1;50(1):130-8
pubmed: 20955788
Brain. 2010 Jun;133(Pt 6):1578-90
pubmed: 20472654
Mov Disord. 2000 Mar;15(2):276-9
pubmed: 10752576
Lancet Neurol. 2009 Mar;8(3):270-9
pubmed: 19233037
Eur J Neurol. 2006 Jan;13(1):89-92
pubmed: 16420399
Cell Death Differ. 2020 Oct;27(10):2781-2796
pubmed: 32341450
Lancet Neurol. 2014 Jul;13(7):676-85
pubmed: 24873720
Mov Disord. 2014 Apr;29(4):463-8
pubmed: 24615741
Redox Biol. 2018 Apr;14:474-484
pubmed: 29096320
FEBS J. 2019 Jun;286(11):2099-2117
pubmed: 30851224
Mov Disord. 2016 May;31(5):742-7
pubmed: 26948290
J Neurochem. 2015 May;133(4):582-9
pubmed: 25580849
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Redox Biol. 2013;1:398-404
pubmed: 25499576
Brain. 2007 Jun;130(Pt 6):1552-65
pubmed: 17405767
J Neurochem. 1994 Apr;62(4):1631-4
pubmed: 8133289
Brain. 2008 May;131(Pt 5):1362-72
pubmed: 18385183
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
J Neurochem. 2000 Feb;74(2):878-81
pubmed: 10646541
J Neuropathol Exp Neurol. 2000 May;59(5):393-7
pubmed: 10888369
Cell Calcium. 2020 Mar;86:102150
pubmed: 31918031
FEBS J. 2021 Jan;288(1):127-141
pubmed: 32338825
Free Radic Biol Med. 2012 Aug 15;53(4):893-906
pubmed: 22705367
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Med Res Rev. 2021 Mar;41(2):770-784
pubmed: 32656815
Mov Disord. 2018 Jul;33(6):1000-1005
pubmed: 29624723
J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):441-5
pubmed: 20360166